A Phase IIa Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 3802876 in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Latest Information Update: 02 Feb 2026
At a glance
- Drugs BI 3802876 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 21 Jan 2026 Planned End Date changed from 11 Feb 2027 to 29 Mar 2027.
- 21 Jan 2026 Planned primary completion date changed from 11 Feb 2027 to 29 Mar 2027.
- 21 Jan 2026 Planned initiation date changed from 29 Jan 2026 to 12 Feb 2026.